ArticleJournal of cardiothoracic surgery2025
The bidirectional regulatory effect of TXNRD2 methylation in patients with chronic heart failure and its nonlinear dose-response relationship with key clinical parameters.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe research focused on examining CpG methylation within the TXNRD2 promoter area in chronic heart failure (CHF) patients, aiming to correlate methylation levels with clinical indexes to guide CHF treatment.
methodsWhole blood samples from 20 CHF patients and 20 healthy controls were analyzed using MALDI-TOF-MS. Methylation levels of CpGs in the TXNRD2-FA42 region were compared between CHF patients, healthy controls, and CHF patients with varying cardiac functions.
resultsTXNRD2-FA42_CpG_3 methylation was lower in CHF patients (P = 0.0407), while TXNRD2-FA42_CpG_8 was higher (P = 0.0183) compared to controls.
conclusionTXNRD2 promoter methylation in CHF patients exhibited bidirectional regulation, potentially influencing coagulation, renal function, and blood routine. These results deepen understanding of CHF pathogenesis and suggest new treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.